Two Approved Drugs. The Same Structural Problem. What the Menopause Market Is Actually Telling Investors.
📕Special note: My book The Billion Dollar Blindspot is available for pre-order on Amazon. It’s currently #5 on Amazon hot new releases in our category. Will you help me make it to #1?
Veozah launched in 2023 as the first non-hormonal oral treatment for menopause symptoms. Two and a half years later, the commercial revolution the category promised has not arrived. Bayer launched its competitor anyway. Here is what that tells capital allocators.
What happened
In May 2023, Astellas’ Veozah became the first FDA-approved non-hormonal oral treatment for the hot flashes and night sweats affecting approximately 75% of women during the menopause transition. Astellas projected US revenues of $375 million in the drug’s first year of commercialisation.
In FY2024, its second full year on market, Veozah generated approximately $220 million globally. In December 2024, the FDA added a black box warning for rare but serious liver injury; the most prominent safety flag the agency can attach to a prescription drug.
Fast forward to October 2025 and Bayer’s Lynkuet received FDA approval for the same indication. It targets both the NK1 and NK3 receptors, a dual mechanism that Veozah does not carry. Importantly, it has no black box warning. Bayer made it commercially available in November 2025 and estimates annual peak sales of approximately €1 billion.
In April 2026, BioPharma Dive published a survey of persistent structural barriers in women's health drug development, noting that despite two approved non-hormonal drugs and a large unaddressed patient population, Veozah has faced slower-than-expected sales and reimbursement complications.
Why it matters
The coverage this week is framing this as a competitive story. Two drugs, same indication, different mechanisms. One with a cleaner safety profile. The question most coverage is asking is which company wins the menopause hot flash market.
That is the wrong question for capital allocators and in this piece, I will cover the one development most coverage has missed entirely, and share three observations on what this category dynamic tells capital allocators in women’s health about where to be positioned before the next announcement.